Last reviewed · How we verify
D745 formulation II — Competitive Intelligence Brief
phase 3
Small molecule
Live · refreshed every 30 min
Target snapshot
D745 formulation II (D745 formulation II) — Chong Kun Dang Pharmaceutical. D745 formulation II is a drug that targets the molecular target to exert its therapeutic effect.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| D745 formulation II TARGET | D745 formulation II | Chong Kun Dang Pharmaceutical | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- D745 formulation II CI watch — RSS
- D745 formulation II CI watch — Atom
- D745 formulation II CI watch — JSON
- D745 formulation II alone — RSS
Cite this brief
Drug Landscape (2026). D745 formulation II — Competitive Intelligence Brief. https://druglandscape.com/ci/d745-formulation-ii. Accessed 2026-05-13.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab